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Toxoplasma gondii is a protozoan parasite that is ubiquitous
in nature and infects a variety of mammals and birds [1]. There
are 3 infectious stages completing the life cycle of T. gondii, in-
cluding tachyzoites (trophozoites), bradyzoites (tissue cysts),
and oocysts containing sporozoites [2]. T. gondii infection has
been reported all over the world. In the United States, National
Health and Nutrition Examination Survey (NHANES) reported
that 10.8% of the general population (6-49 years of age) and
11.0% of women (15-44 years of age) have Toxoplasma-specif-
ic IgG antibodies [3]. Toxoplasmosis is not a severe or critical
infectious disease in healthy adults [1]. However, toxoplasmo-
sis is sometimes fatal in immunosuppressed conditions, such
as AIDS [4,5] and transplantation patients as well as pregnant
women [6,7]. Toxoplasmosis in AIDS patients mainly affects
the brain and is frequently fatal [8]. 
Most previous studies have focused on the pathogenesis, clin-
ical, and epidemiologic aspects of toxoplasmosis. However, sev-
eral recent studies are highlighted by the duality of parasitic in-
fections, i.e., parasites are occasionally helpful rather than harm-
ful for the prognosis of some other diseases. For instance, T. gon-
dii has been suggested as a protozoan parasite for immunother-
apy of other diseases. The growth of Lewis lung carcinoma is
inhibited following an oral infection with T. gondii ME49 strain
[9]. Mice injected with both T. gondii and cancer cells showed
an increase in CD8+ T-cells, IFN-g mRNA levels, and serum IgG2a
titers. In addition, hemoglobin concentration inside the Matrigel
plug inserted into mice was decreased by T. gondii infection, and
a decrease in the tumor mass by inhibition of angiogenesis was
suggested [9]. IFN-g, TNFRp55, and iNOS are important for the
inflammatory lesion and tissue parasitism after T. gondii infec-
tion [10]. IFN-g, TNF family ligands, and iNOS are also known
to be associated with anti-tumorigenic mechanisms by macro-
phages and NK cells [11-13]. However, the mechanism is not
yet fully elucidated and the possibility of direct immuno-mod-
ulation by antigenic proteins of T. gondii has not been deter-
mined.
The present study investigated the effects of T. gondii lysate
antigens (TLA) on tumorigenesis in BALB/c mice. For this pur-
pose, a murine lymphoma cell line, sarcoma-180 (S-180) cells,
was used for tumor generation and successfully created solid
tumors (S-180 tumors). The anti-tumor effects were determined
by measuring the tumor size and weight, and the expression of
CD31 in the tumor tissue. The present study was performed to
observe the changing patterns of the tumor size and CD31 ex-
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pression in the S-180 tumor mass in mice injected with TLA or
formalin-fixed T. gondii tachyzoites. 
Female BALB/c mice were purchased from ORIENT BIO Ani-
mal Center (Seongnam, Gyeonggi-do, Korea). Mice were housed
at room temperature (20-23℃) on a 12-hr light and 12 hr-dark
cycle, with unlimited supplies with food and water sterilized by
irradiation and autoclaving. All experiments using mice were
performed according to the ethical standards formulated from
the IACUC (SNU-090102-3) in the Seoul National University.
TLA were prepared according to the procedure described previ-
ously, with a slight modification [14]. Briefly, tachyzoites of the
virulent T. gondii RH strain were obtained from the peritoneal
exudate of intraperitoneally-infected mice. The exudate was pas-
sed twice through a 25-gauge needle and followed by passing
through filter membranes of 5 mm pore size to remove debris
and host cells. The isolated parasites were washed, resuspended
in phosphate-buffered saline (pH 7.4), and sonicated on ice.
The supernatant (TLA) was filter-sterilized through a 0.22 mm
pore size membrane. The protein concentration of TLA was
determined by the BCATM‚ Protein Assay Kit (Thermo Scientific,
Rockford, Michigan, USA) and stored at -70℃ until used. Tu-
mors were generated by subcutaneous injection of a mixture of
1.0 × 107 S-180 cells (KCLB 40066, Korean Cell Line Bank,
Seoul, Korea) and 500 ml of growth factor-reduced BD MatrigelTM‚
(BD Science, Miami, Florida, USA) at the mid-backs of 6-week-
old BALB/c mice [9,15].
When tumors were grown to an average volume of approxi-
mately 40 mm3 on day 14 after the injection of S-180 cells, mice
were randomly divided into the following 3 experimental groups
(N = 3 for each group); TLA, formalin-fixed T. gondii, and PBS.
After fixation of tachyzoites with formalin for 20 min, tachy-
zoites were centrifuged at 3,000 rpm, 4℃ for 10 min and wash-
ed 5 times to remove formalin completely. These formalin-fixed
tachyzoites were injected into the tumor mass of tumor-bear-
ing mice. The residual formalin in the last washing solution was
analyzed by high performance liquid chromatography (HPLC)
to prove the safety of the injection into mice; 10 ml of the last
washing solution was applied to HPLC (Gilson, Middleton,
Wisconsin, USA). In this experiment, 5 × 105 formalin-fixed
tachyzoites were injected into the tumor mass once during the
experimental period. However, TLA diluted in PBS was injected
with 50 mg/100 ml twice weekly. The control group was injected
with 100 ml PBS into the tumor mass. An Ultra-Fine II Insulin
Syringe (BD Science) was used to minimize the tissue damage
by twice weekly TLA or PBS injections. The tumor size was mea-
sured using a caliper and calculated by the following formula:
length ×width ×height × 0.5 [16]. The tumor weight was also
measured once after the mice were sacrificed (data not shown).
Tumor proteins were prepared in RIPA buffer (1 × PBS, 1%
NP-40, 0.5% sodium deoxycholate, and 0.1% sodium dodecyl
sulfate) supplemented with 1 × Roche complete Mini protease
inhibitor cocktail (Roche, Indianapolis, Indianapolis, USA). The
protein concentration was measured using the BCA method
(Thermo Scientific). The statistics programs used were SPSS
12.0K and SigmaPlot 10.0. A P-value < 0.05 was regarded as
significant. 
Tumor sizes were measured on day 9 post-injection of TLA
or formalin-fixed T. gondii, then the tumor masses were isolat-
ed from the mice after sacrifice (Fig. 1). The tumor sizes of TLA-
(1,731 ± 366.5 mm3) or T. gondii-injected (2,200 ± 669.6
mm3) groups were smaller than those of PBS-injected control
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Fig. 1. Comparison of tumor sizes among PBS-, formalin-fixed T.
gondii tachyzoites-, and T. gondii lysate antigen (TLA)-group. (A)
Tumor sizes of T. gondii-injected and TLA-treated mice were small-
er than them of control mice. (B) Tumor masses were isolated from
mice at day 9 post-PBS-, -T. gondii-, or -TLA-injection. Tumors of TLA
group were significantly smaller than control group (P = 0.00153).
group (4,667 ± 549.4 mm3). These observations were in agree-
ment with the results of different tumors used in T. gondii in-
fections, including Lewis lung carcinoma [9] and WEHI-164
fibrosarcoma [17]. The TLA-treated group was significantly small-
er than the control group in the tumor size (P = 0.00153). Both
formalin-fixed T. gondii-injection and TLA-treatment showed
the same effects on the inhibition of tumor growth and the effect
would be augmented by a repeated TLA injection. CD31 is ex-
pressed on platelets and endothelial cells, involved in cell recog-
nition, motility, and signaling in the biological process, and
suggested as an important marker of angiogenesis in tumors
[18]. Expression of CD31 (PECAM-1) was investigated by im-
munohistochemical staining of the sectioned tumor mass and
the results showed a decrease in spots stained with anti-CD31
mAb in TLA- or T. gondii-injected tumors (data not shown). The
CD31 protein levels were determined in the tumor mass and
appeared to be decreased in the TLA- and T. gondii-treatment
groups compared to the control group on Western blots (Fig. 2).
Because CD31 is highly expressed on tumor tissues in a general
state of angiogenesis [18], our results may be correlated with
anti-angiogenesis (Figs. 1B, 2). Although it is known that im-
mune responses after T. gondii infection are related with anti-
cancer effects in tumor-bearing mice [9,18], further studies are
needed using TLA to better elucidate anti-angiogenesis. 
Our study focused on the effects of T. gondii-antigenic pro-
teins, as well as T. gondii injection, on anti-tumorigenic effects.
The results showed a decrease in CD31, a marker of angiogene-
sis, after TLA injection into the tumor mass. This result demon-
strates the anti-tumorigenic effect of a protozoan parasite, T.
gondii, may be induced by the intervention of molecular mech-
anisms inhibiting vascular formation by T. gondii lysate proteins.
However, the relationship between the immune response in-
duced by TLA- or formalin-fixed T. gondii-injection and the sup-
pression of tumor growth must not be overlooked. In this regard,
we observed the increase of IL-12 in TLA-injected tumor-bear-
ing mice (data not shown). IL-12 is related to suppression of
angiogenesis when tumors are produced [19,20]. IL-12 has also
been shown to be induced by T. gondii antigens (TLA) in pro-
monocytic cell line cultures (THP-1 cells) [21]. Considering the
possible mechanisms by which TLA exerts an effect (a direct
anti-tumorigenic effect, or indirect immune response), this study
supports the results of previous studies reporting anti-angioge-
nesis effects of T. gondii infection. 
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